Join Mintz and ML Strategies for a webinar on a spectrum of legal issues companies in the life sciences industry are facing during this complicated period. The program will cover issues of:

Employment Law

• Defining “essential” businesses

• What to do if an employee in your essential business chooses not to work

• How/what to communicate when an employee tests positive

• Communications regarding a positive test

FDA

• Emergency use authorizations (EUAs) and enforcement discretion policies

• Program setup for developers of potential COVID-19 therapeutics

• Actions to help alleviate regulatory burdens on existing product sponsors in the life sciences industry

Clinical Trials

• Regulatory authority accommodations for ongoing clinical trials that may be affected by COVID-19 and regional restrictions

• Key considerations for sponsors and sites regarding ongoing and planned clinical trials

M&A

• State of the M&A deal market

• Impacts on deal processes and associated timeline

• Allocating pandemic risk (MAC clauses come into focus)

Capital Markets

• State of the public capital markets

• Recent SEC developments related to COVID-19

• Impacts on financing options for life sciences companies

Federal Legislation

• Accessing funds for businesses creating COVID-19 diagnostics, therapeutics or vaccines

• Financial assistance for businesses provided by CARES Act and other legislation

Moderator

Aaron L. Josephson  Senior Director, ML Strategies

Marc D. Mantell  Member, Mergers & Acquisitions Practice, Mintz

H. Andrew Matzkin  Member, Employment, Labor & Benefits Practice, Mintz

John T. Rudy Member, Securities & Capital Markets Practice, Mintz

Benjamin M. Zegarelli Associate, Health Law Practice / Clinical Trials & Research, Mintz